Skip to main content Skip to section navigation Skip to footer
Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Functional Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
    • Corporate Presentation
  • Clinical Trials & Patients
    • Clinical Trials
    • REFRαME
    • Patients
      • Patient Resources
      • Commitment To Patients
      • Compassionate Use Access
  • Science
    • Pipeline
    • iADCs & Antibody-Drug Conjugates
    • XpressCF+®
    • cGMP Facility
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • News
    • News Releases
    • Presentation & Publication
    • Events
    • Events Audio Replays
  • Join Us
    • The Way We Work
    • Join Our Team
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

News Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • News Releases
    • Events & Audio Replays
    • Email Alerts
  • Company Info
    • Company Profile
    • Management Team
    • Functional Leadership Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • News Releases
  • Events & Audio Replays
  • Email Alerts
Apr 29, 2022 5:00 pm EDT
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 8, 2022 1:00 pm EDT
Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022
Apr 5, 2022 7:00 am EDT
Sutro Biopharma to Present at the 21st Annual Needham Virtual Healthcare Conference
Mar 30, 2022 4:05 pm EDT
Sutro Biopharma Presented on Advances in Novel Immunostimulatory Antibody-Drug Conjugate Modality at the 12th Annual World ADC
Mar 3, 2022 7:00 am EST
Sutro Biopharma to Participate in the Cowen 42nd Annual Healthcare Conference
Feb 28, 2022 4:35 pm EST
Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones
Jan 6, 2022 7:00 am EST
Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
Jan 5, 2022 4:30 pm EST
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
Dec 27, 2021 7:00 am EST
Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China
Dec 27, 2021 7:00 am EST
Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Page 21
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
Sutro Biopharma Corporate Site

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2025 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.